A Phase 2 interventional study of CC-10004 and CC-10004 in Psoriasis, sponsored by Amgen. Completed at 31 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 11th largest by enrollment, is the only one that started in 2006, is one of 10 in phase 2, and was the 3rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 23rd largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2006, is one of 8 in phase 2, and was the 15th registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The information obtained from the study will aid in the design of future clinical trials and to establish the safety and efficacy of CC-10004.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg of CC-10004 daily
Drug: CC-10004
CC-10004 twice daily
Drug: CC-10004
Placebo arm
Drug: Placebo
To compare the clinical efficacy of 2 oral doses of CC-10004 with placebo when taken for 12 weeks in subjects with moderate-to-severe plaque-type psoriasis
Time frame: 12 weeks
To evaluate the safety of CC-10004 compared with placebo in subjects with moderate-to-severe placque-type psoriasis
Time frame: 12 weeks
To evaluate the effects of CC-10004 compared to placebo on the quality of life in subjects with moderate-to-severe plaque-type psoriasis.
Time frame: 12 weeks
Ran from Apr 2006 to primary completion in Feb 2007, 10 months.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast